FY2026 EPS Estimates for DexCom Decreased by Leerink Partnrs

DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at Leerink Partnrs lowered their FY2026 earnings per share (EPS) estimates for DexCom in a research report issued on Thursday, October 24th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings per share of $2.46 for the year, down from their prior forecast of $2.49. The consensus estimate for DexCom’s current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom’s FY2027 earnings at $2.77 EPS and FY2028 earnings at $3.14 EPS.

A number of other equities analysts have also recently weighed in on DXCM. Leerink Partners cut their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Friday. Piper Sandler reissued an “overweight” rating and issued a $90.00 target price on shares of DexCom in a report on Monday, August 26th. Finally, Raymond James lowered their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday. Six analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $72.10 on Monday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company’s 50-day moving average price is $70.11 and its 200 day moving average price is $97.65. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $28.67 billion, a price-to-earnings ratio of 46.69, a PEG ratio of 2.26 and a beta of 1.18.

Institutional Investors Weigh In On DexCom

Institutional investors have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board lifted its position in shares of DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after buying an additional 435,401 shares during the period. Massachusetts Financial Services Co. MA raised its stake in DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after acquiring an additional 353,019 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in DexCom by 53.5% during the third quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock worth $66,352,000 after acquiring an additional 345,114 shares in the last quarter. Bellevue Group AG lifted its holdings in shares of DexCom by 33.5% during the first quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock valued at $169,380,000 after acquiring an additional 306,604 shares during the period. Finally, Magnetar Financial LLC acquired a new stake in shares of DexCom in the 2nd quarter valued at $31,793,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,824 shares of company stock worth $126,390. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.